Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GW Pharma, Otsuka Extend Cannabinoid Research Collaboration
GW Pharma and Otsuka signed the agreement in July 2007 with a three year term, and the collaboration is now extended upto the end of June 2013. As
GW Pharma and Otsuka signed the agreement in July 2007 with a three year term, and the collaboration is now extended upto the end of June 2013. As
The new laboratory is expected to deliver site support services to clinical investigators throughout China and offers overall benefits including shorter shipping distances between clinical sites and existing
Ganeden Biotech and Glanbia Nutritionals are expected to provide a stick pack containing an immune health micronutrient premix from Glanbia Nutritionals and GanedenBC30. GanedenBC30 is a probiotic that
Omnaris HFA is an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients. Ciclesonide is the active ingredient in
As per the terms of the licensing and supply agreement, ULURU is expected to get an upfront licensing payment, milestone payments based on regulatory approvals and sales performance
Aestus is expected to develop the product as ATx08-001, a novel therapeutic for the treatment of neuropathic pain. The first clinical trial will start later this year. Aestus
The program covers glucagon analogs that may provide greater convenience and ease-of-use than the current recombinant glucagon for the treatment of severe hypoglycemia. The program includes MAR531, a
Revlimid is used for the treatment of elderly patients with newly diagnosed multiple myeloma. Celgene has presented the trial data at the European Haematology Association’s annual congress in
The agreement is intended to foster oncology research and technology development in the areas of cancer diagnostics, cancer biology pre-malignancies, genetic models of disease, and profiles of the
Abbott had received independent 510(k) clearances for both the Abbott RealTime Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) assay and the Abbott m2000 System. They are required to be used together